# US 2013/0210861 A1 · Methods and compositions for managing cardiovascular disease associated with chronic kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210861 A1
- Document ID: US20130210861A1
- Status: Published application
- Kind: A1
- Application number: 13/709,057
- Filed: 2012-12-09
- Published: 2013-08-15
- Earliest claimed: 2011-12-09
- Inventors: Ashutosh M. SHUKLA; Sudhir V. SHAH
- Web page: https://patentgrep.com/patent/US20130210861A1

## CPC

- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods of treating cardiovascular disease in patients predisposed to or afflicted with kidney disease, particularly chronic kidney disease, are described. In such methods, therapeutically effective amounts of chloroquine-based compounds, for example, hydroxychloroquine, are administered to prevent or otherwise ameliorate arthrosclerosis and other cardiovascular diseases.

## Claims

### Claim 1

A method selected from the group consisting of:
(a) a method of preventing cardiovascular disease (CVD) in a patient known to have or suspected of having chronic kidney disease (CKD);
(b) a method for reducing cardiovascular disease severity in a patient known to have or suspected of having CKD; and
(c) a method of preventing cardiovascular disease progression in a patient known to have or suspected of having chronic kidney disease (CKD),
comprising administering to a patient known to have or suspected of having CKD an effective amount of chloroquine or a chloroquine derivative compound to prevent, reduce the severity of, or prevent the progression of CVD.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the chloroquine derivative compound is selected from the group consisting of hydroxychloroquine and 4-aminoquinoline.

### Claim 3 (depends on 1)

A method according to claim 1 wherein the chloroquine derivative compound is hydroxychloroquine.

### Claim 4 (depends on 3)

A method according to claim 3 wherein the effective amount of hydroxychloroquine comprises about 100 to about 400 mg of hydroxychloroquine per day.

### Claim 5 (depends on 4)

A method according to claim 4 wherein hydroxychloroquine is administered more than once per day.

### Claim 6 (depends on 4)

A method according to claim 4 wherein about 200 mg of hydroxychloroquine is administered twice per day.

### Claim 7 (depends on 1)

A method according to claim 1 wherein the cardiovascular disease is selected from the group consisting of myocardial infarction, congestive heart failure, and stroke.

### Claim 8 (depends on 1)

A method according to claim 1 wherein preventing cardiovascular disease progression comprises reducing need for a revascularization procedure.

### Claim 9 (depends on 1)

A method according to claim 1 that comprises administration of chloroquine or a chloroquine derivative compound to the patient for at least about 1-4 weeks, about 1-12 months, and about 1-10 or more years.

### Claim 10

A method of cardioprotection in a patient known to have or suspected of having chronic kidney disease (CKD), comprising administering to a patient known to have or suspected of having CKD a cardioprotective amount of chloroquine or a chloroquine derivative compound.

### Claim 11

A method of reducing risk of mortality in a patient known to have or suspected of having chronic kidney disease (CKD), comprising administering to a patient known to have or suspected of having CKD an amount of chloroquine or a chloroquine derivative compound effective to reduce risk of patient mortality, optionally patient mortality associated with cardiovascular disease (CVD).
